Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence
Authors
Keywords
-
Journal
Scientific Reports
Volume 6, Issue 1, Pages -
Publisher
Springer Nature
Online
2016-03-11
DOI
10.1038/srep22976
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sorafenib resistance and JNK signaling in carcinoma during extracellular matrix stiffening
- (2014) Thuy V. Nguyen et al. BIOMATERIALS
- New biological perspectives for the improvement of the efficacy of sorafenib in hepatocellular carcinoma
- (2014) Antoine Galmiche et al. CANCER LETTERS
- Alternative Mammalian Target of Rapamycin (mTOR) Signal Activation in Sorafenib-resistant Hepatocellular Carcinoma Cells Revealed by Array-based Pathway Profiling
- (2014) Mari Masuda et al. MOLECULAR & CELLULAR PROTEOMICS
- In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer
- (2014) Ramona Rudalska et al. NATURE MEDICINE
- JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
- (2014) Masatoshi Kudo et al. Liver Cancer
- Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib
- (2013) D. Chen et al. EJSO
- Label-retaining liver cancer cells are relatively resistant to sorafenib
- (2013) Hong-Wu Xin et al. GUT
- Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?
- (2013) Carmen Berasain GUT
- αB-crystallin complexes with 14-3-3ζ to induce epithelial-mesenchymal transition and resistance to sorafenib in hepatocellular carcinoma
- (2013) Xiao-Yong Huang et al. HEPATOLOGY
- The antiangiogenic ceiling in hepatocellular carcinoma: does it exist and has it been reached?
- (2013) Ghassan K Abou-Alfa et al. LANCET ONCOLOGY
- Predictive Biomarkers of Antiangiogenic Therapy for Advanced Hepatocellular Carcinoma: Where Are We?
- (2013) Yu-Yun Shao et al. Liver Cancer
- CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma
- (2012) Catia Giovannini et al. AMERICAN JOURNAL OF PATHOLOGY
- Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysis
- (2012) T. Pressiani et al. ANNALS OF ONCOLOGY
- Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma
- (2012) S Hagiwara et al. BRITISH JOURNAL OF CANCER
- Molecular mechanisms of sorafenib action in liver cancer cells
- (2012) Melchiorre Cervello et al. CELL CYCLE
- Second-Line Therapies in Hepatocellular Carcinoma: Emergence of Resistance to Sorafenib
- (2012) A. Villanueva et al. CLINICAL CANCER RESEARCH
- Epidemiology of Viral Hepatitis and Hepatocellular Carcinoma
- (2012) Hashem B. El-Serag GASTROENTEROLOGY
- Role of sorafenib in the treatment of advanced hepatocellular carcinoma: An update
- (2012) Angela Gauthier et al. HEPATOLOGY RESEARCH
- Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells
- (2012) Marie-José Blivet-Van Eggelpoël et al. JOURNAL OF HEPATOLOGY
- Hepatocellular carcinoma
- (2012) Alejandro Forner et al. LANCET
- Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib
- (2011) M. Pinter et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis
- (2011) Ying-Hong Shi et al. Autophagy
- Global cancer statistics
- (2011) Ahmedin Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Expression and prognostic role of pan-Ras, Raf-1, pMEK1 and pERK1/2 in patients with hepatocellular carcinoma
- (2011) L. Chen et al. EJSO
- JNK: A double-edged sword in tumorigenesis
- (2011) Francisco Javier Cubero et al. HEPATOLOGY
- Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma
- (2011) Satoshi Shimizu et al. INTERNATIONAL JOURNAL OF CANCER
- Activation of Phosphatidylinositol 3-Kinase/Akt Signaling Pathway Mediates Acquired Resistance to Sorafenib in Hepatocellular Carcinoma Cells
- (2011) K.-F. Chen et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- IL-1β induces ER stress in a JNK dependent manner that determines cell death in human pancreatic epithelial MIA PaCa-2 cells
- (2010) Gaurav Verma et al. APOPTOSIS
- Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study
- (2009) Sandrine Faivre et al. LANCET ONCOLOGY
- Molecular targeted therapies in hepatocellular carcinoma
- (2008) Josep M. Llovet et al. HEPATOLOGY
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial
- (2008) Ann-Lii Cheng et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- The pivotal role of c-Jun NH2-terminal kinase-mediated Beclin 1 expression during anticancer agents-induced autophagy in cancer cells
- (2008) D-D Li et al. ONCOGENE
- MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma
- (2008) F Fornari et al. ONCOGENE
- Statistical methods for efficiency adjusted real-time PCR quantification
- (2007) Joshua S. Yuan et al. Biotechnology Journal
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now